Examines cognitive decline and biomarker changes in preclinical Alzheimer’s disease, indicating potential diagnostic utility.
To examine whether plasma glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, predicts cognitive decline, clinical progression, and biomarker changes in preclinical Alzheimer’s disease (AD), and whether these associations differ by sex or amyloid status.
No takes yet. Share an insight, caveat, or question.
Ezzati et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: